Introduction: The Global Task Force for Cholera Control (GTFCC) developed a Global Roadmap for Ending Cholera by 2030 emphasizing the need for targeted multisectoral interventions in priority areas. In 2023 for the first time in Cameroon, identification of PAMIs for cholera control was conducted, following the 2023 GTFCC guidelines. We hereby describe experience of PAMIs identification in a cholera high-burden country. Methods: In August 2023, a multisectoral technical team was set up, under the leadership of the Ministry of health to conduct identification of PAMIs. Stakeholders were briefed on GTFCC guidelines. A retrospective (January 2016- September 2023) descriptive study was conducted in all the 10 regions of Cameroon. Data were collected from DHIS-2, national cholera line lists, situation reports, databases from the Centre Pasteur of Cameroon and the National Public Health Laboratory. These datasets were entered in the GTFCC tool for automated analysis. An initial list of PAMIs was identified based on a priority index using four indicators: cholera incidence, mortality, persistence, and positivity. In December 2023, we conducted a multisectoral validation workshop, during which the threshold of 9 was set for PAMIs prioritization and a second prioritization done using vulnerability factors. Results: Overall, 48 health districts (25% of all health districts) were identified as PAMIs, 35 PAMIs using the priority index and 13 based on vulnerability factors. About 11 488 089 people (41% of the country population) live in these PAMIs from which 93% of cholera cases were reported over the past 8 years. The Centre, Littoral, South-West, and the Far North regions are home to 66% of PAMIs. Conclusion: Identification of PAMIs was successfully conducted in Cameroon and provided scientific evidence for decision-making to level up cholera preparedness and prevention. The ownership and leadership of governmental main stakeholders were critical. Data availability facilitated this exercise.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors